Global Call To Action on Familial Hypercholesterolemia: Aims to Improve Diagnosis and Treatment Worldwide

The FH Foundation and the World Heart Federation announced today a Global Call to Action on familial hypercholesterolemia (FH), a vastly under-recognized and poorly managed public health concern.

Published in JAMA Cardiology and authored by a global panel of scientific experts, advocacy leaders, public health officials, and individuals with FH from 40 countries, the report notes glaring gaps in screening and guideline-based care for FH, the most common cause of early and aggressive heart disease. 

FH is an inherited metabolic disorder found in all races and ethnicities and impacts 34 million people worldwide. FH causes high LDL-cholesterol from birth and should be diagnosed and treated within the first two decades of life. Left untreated, individuals with FH have a 20-times higher risk of illness and death from cardiovascular disease (CVD). However, if diagnosed and treated, heart attacks, strokes and the need for surgery can be prevented.

The international coalition was convened by the FH Foundation and World Heart Federation to reexamine and update key recommendations issued by the World Health Organization (WHO) in their report on Familial Hypercholesterolemia in 1998.  In the 20 years since that report, few of these recommendations have been systematically implemented on a country-by-country basis, leaving nine out of 10 people born with FH undiagnosed. 

“Familial hypercholesterolemia represents an unprecedented opportunity for prevention of heart disease around the world,” said Katherine Wilemon, Founder and CEO of the FH Foundation.  “Our aim initiating this Call to Action is to highlight that we have had the scientific understanding, and effective therapies, to stop inherited coronary heart disease, but have allowed generations of families to go uncared for.  It is time to address Familial hypercholesterolemia as a public health priority.”

The FH Global Call to Action coalition cites mounting scientific data, the commercialization of novel therapies, and technological advances as further impetus for public health officials and governments to commit to early screening and coordinated lifetime care for this large and vulnerable population.

“The success of the concrete and actionable recommendations we issue today will depend on support from governments, which is why we are jointly addressing them as a global community now,” said Jean-Luc Eiselé, CEO of the World Heart Federation. “Each of the partnering organizations is committed to advocating to improve and expand FH care in their countries. The Global Call to Action on FH is an unprecedented opportunity to prevent premature cardiovascular disease in future generations worldwide.”

Source: The FH foundation

Tags: Familial Hypercholesterolemia, Cardiology, LDL-cholesterol, heart disease, Heart drugs, heart medicine manufacturer, Generic latest news, International drug news

About Taj Pharma:

Taj Pharmaceuticals is the global leader in generics and one of the India’s top ten pharmaceutical companies. Taj Pharma India play a leading role in therapeutic areas such as cancer, virology and transplantation. The combined strengths of Taj Pharma generics and pharmaceuticals businesses, coupled with expertise in the emerging genetic sciences, equip us to develop integrated healthcare solutions and therapeutic approaches tailored to individual patients’ needs. Taj Pharmaceutical’s products and services address the entire healthcare spectrum, from screening for genetic risk factors, to preventing, diagnosing and treating disease, and monitoring the treatment response.Taj Pharma India delivers a unique contribution to better healthcare. Taj Pharma India aim to reduce suffering and improve health and quality of life of people all around the world.